SEATTLE, November 7, 2017 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced topline interim results from the LIGHTSITE I trial for treatment of dry age-related macular degeneration (AMD) trial utilizing its LT-300 device. The 30-subject pilot study funded from… Continue reading

Posted on November 7th, 2017 in Press Releases | Comments Off on LumiThera Unveils LIGHTSITE I Dry AMD Clinical Interim Data

SEATTLE, October 31, 2017 /PRNewswire/ — LumiThera Inc., a clinical stage private medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed the Series B round of financing. The company raised $5.5M to support further development of its LT-300 device for the treatment for dry Age-related… Continue reading

Posted on October 31st, 2017 in Press Releases | Comments Off on LumiThera Closes Series B Round of Financing

A pilot clinical study lead by LumiThera founders from The Toronto and Oak Ridge Study of Photobiomodulation (TORPA) looked at the effect of photobiomodulation (PBM) in the treatment of dry AMD. The TORPA data for dry AMD patient’s showed clinically and statistically significant improvement in both visual acuity and contrast sensitivity. TORPA Clinical Study The… Continue reading

SEATTLE, April 18, 2017 /PRNewswire/ — LumiThera® Inc., a clinical stage medical device company focused on delivering non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced it has been awarded the prestigious “MOST INNOVATIVE AND PROMISING MEDTECH & E-HEALTH COMPANY” during Biovision 2017 in Lyon, France. Biovision is a high-level investor event connecting… Continue reading

Posted on April 18th, 2017 in Press Releases | Comments Off on LumiThera Named Most Innovative And Promising Medtech & E-Health Company At Biovision 2017

Non-invasive photobiomodulation may help dry age-related macular degeneration by causing regression of drusen and improving retinal function with benefits in visual acuity and contrast sensitivity. By Lynda Charters; Reviewed by Graham Merry, MBBS, and Marion R. Munk, MD, PhD Photobiomodulation (PBM) may be a new non-invasive, light-based treatment for patients with dry age-related macular degeneration… Continue reading

Posted on September 22nd, 2016 in Research Articles | Comments Off on Dry AMD Therapy Evolves with Photobiomodulation

SEATTLE, May 5, 2016 /PRNewswire/ — LumiThera® Inc., a late stage developmental medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease today announced that Graham Merry, MBBS presented clinical data results from the TORPA II study in Dry Age-Related Macular Degeneration (AMD) subjects at the Association for Research in Vision… Continue reading

Posted on May 6th, 2016 in Press Releases | Comments Off on LumiThera Presents Results of TORPA II Clinical Study at the Association for Research in Vision and Ophthalmology (ARVO) Conference

SEATTLE, April 27, 2016 /PRNewswire/ — LumiThera ® Inc., a late-stage developmental medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has been awarded the prestigious “MOST PROMISING AND INNOVATIVE CATALYZER AWARD” during Biovision 2016, Lyon, France. Biovision is a high-level investor event connecting industrial partners, financial… Continue reading

Posted on April 28th, 2016 in Press Releases | Comments Off on LumiThera Named Most Promising and Innovative Catalyzer Startup at BIOVISION 2016

SEATTLE, March 24, 2016 /PRNewswire/ — LumiThera Inc., a developmental stage medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has obtained Health Canada approval of their LIGHTSITE clinical study to treat dry Age-related Macular Degeneration (AMD) subjects. The pilot clinical trial is in part sponsored by… Continue reading

Posted on March 24th, 2016 in Press Releases | Comments Off on LumiThera Obtains Approval by Health Canada to Start Age-related Macular Degeneration Clinical Study

SEATTLE, Sept. 29, 2015 /PRNewswire/ — LumiThera Inc., a developmental stage medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a two small business innovative research (SBIR) phase I grants from the National Institute of Health (NIH) and the division of the National… Continue reading

Posted on September 30th, 2015 in Press Releases | Comments Off on LumiThera Receives Notice of Awards for two National Eye Institute Grants

SEATTLE, May 27, 2015 /PRNewswire/ — LumiThera Inc., a developmental stage medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, announced today that they were awarded a Washington State Life Sciences Discovery Fund (LSDF) commercialization grant. LumiThera was 1 of 3 recipients of the LSDF matching grants worth $500,000 to… Continue reading

Posted on May 28th, 2015 in Press Releases | Comments Off on LumiThera Receives LSDF Commercialization Grant Award